Wysa vs Butterfly Network

Butterfly Network has a disclosed valuation of $957M, while Wysa's valuation is not publicly available, making a direct size comparison difficult. Butterfly Network employs 500-1000 people.

Butterfly Network has raised more in total funding at $370M, compared to Wysa's $30M — a gap of $340M. Combined, the two companies have completed 8 known funding rounds.

Butterfly Network leads with an Awaira Score of 85/100, while Wysa sits at 63/100. That 22-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Wysa was founded by Jo Aggarwal in 2015. Butterfly Network was founded by John Martin in 2011. Visit each company's profile on Awaira for a full founder biography.

Wysa: Wysa is an AI mental health platform that provides evidence-based cognitive behavioral therapy techniques through a conversational AI chatbot, offering anonymous, stigma-free mental health support accessible via smartphone at any hour. The platform uses clinically validated CBT, DBT, and mindfulness exercises delivered conversationally, and provides a step-up pathway to licensed human therapists for users requiring more intensive support.\n\nThe company raised approximately $30M in Series B funding and has deployed its platform to over five million users globally, including through enterprise employee wellness programs, NHS partnerships in the UK, and healthcare system integrations in the United States and India. Wysa has published peer-reviewed clinical evidence demonstrating statistically significant improvements in depression and anxiety scores.\n\nMental health care access is a global crisis with a severe therapist shortage that AI can meaningfully address at the first-line support level. Wysa's combination of clinical validation, enterprise and payer relationships, and scalable AI delivery model positions it as one of the more credible players in the crowded digital mental health space. Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Butterfly Network operates in the AI Healthcare sector and is headquartered in United States. Founded in 2011 by John Martin, Butterfly Network has raised $370M in total funding, achieving a valuation of $957M as of its latest round. The company's funding journey includes a Seed of $11.1M in 2011, a Series A of $29.6M in 2012, a Series B of $66.6M in 2014, a Series C of $114.7M in 2015, a Series D of $148M in 2016. With approximately 500-1000 employees, Butterfly Network has established itself as a Public-stage player in the AI Healthcare market. The company holds an Awaira Score of 85/100, reflecting its strong position across valuation, funding trajectory, team scale, and market influence. Butterfly Network competes in a rapidly evolving segment alongside other AI Healthcare companies. Based in United States, Butterfly Network is part of a growing international AI ecosystem attracting talent and investment. The AI Healthcare space has attracted significant investment in recent years, with companies racing to capture enterprise and consumer demand for AI-powered solutions.

Butterfly Network got there first, launching in 2011 — that's 4 years of extra runway. Wysa didn't arrive until 2015. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Wysa has about 50-200 employees; Butterfly Network has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Wysa and Butterfly Network compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.